Lin Mu

Lin Mu

Auto-generated profile, based on publicly available information

Lin Mu

Affiliations Eye and ENT Hospital of Fudan University, Shanghai, China, Shanghai Research Center of Ophthalmology and Optometry, Shanghai, China, Institute of integrative opthalmology and otolaryngology, Eye and ENT Hospital of Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2023 in Advanced Engineering Informatics
Verified
Journal Article
Closed access
FLFuzheng Liu
Fuzheng Liu
FZFaye Zhang
Faye Zhang
XGXiangyi Geng
Xiangyi Geng
LMLin Mu
Lin Mu
LZLei Zhang
Lei Zhang
JGJunwei Gao
Junwei Gao

30 December 2022 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
LMLin Mu
Lin Mu
DWDahu Wang
Dahu Wang
ZDZhiguo Dong
Zhiguo Dong
FZFuwen Zhang
Fuwen Zhang
XWXiaoyu Wu
Xiaoyu Wu
YZYinjian Zhang
Yinjian Zhang
Purpose. This study aimed to measure the concentrations of ferroptosis-related biomarkers, namely, iron (Fe), lipid peroxide (LPO), reactive oxygen species (ROS), glutathione peroxidase-4 (GPX4), and glutathione (GSH) in DR in the attempt to evaluate the diagnostic performance of these biomarkers. Methods. This study included 30 NPDR patients, 30 PDR patients, and 30 healthy subjects matched in age and sex. The concentrations of Fe, LPO, ROS, GPX4, and GSH in serum of the subjects were measured. Results. Compared with the normal group, GPX4 and GSH concentrations were significantly lower, and LPO, Fe, and ROS concentrations were significantly higher in DR patients. Compared with the PDR group, the NPDR group had higher concentrations of LPO, Fe, and ROS and lower concentrations of GPX4 and GSH, but there was no statistical difference in Fe, GPX4, and GSH. ROC curve shows that ferroptosis-related biomarkers have accumulated accuracy in NPDR and PDR. Conclusion. This study shows that ferroptosis-related biomarkers may be involved in the pathological process of DR and can be used as one of the biomarkers of DR.

23 August 2017 in Oncology Letters
Verified
Journal Article
Open access
PDF file
TWTianjiao Wang
Tianjiao Wang
ZZZhumei Zhuang
Zhumei Zhuang
PZpeng zhang
peng zhang
YWYueyue Wang
Yueyue Wang
LMLin Mu
Lin Mu
YYYuhui Yuan
Yuhui Yuan
Pancreatic carcinoma (PC) is a deadly form of cancer with poor overall survival. Currently, chemotherapy such as gemcitabine and 5-fluorouracil (5-FU) are the most popular medications that can improve survival, but rapid drug-resistance makes the search for more effective drugs urgent. Upon looking for natural components to treat PC, it was found that arenobufagin, a cardiac glycosides-like compound, showed significant effects on the gemcitabine-resistant pancreatic carcinoma cell line Panc-1 and the gemcitabine-sensitive cell line ASPC-1 at nanomolar concentrations. The present study used MTT and clonogenic survival assays to examine survival and proliferation, and western blotting to assess changes in the associated mitogen activated protein kinase and phosphoinositide 3-kinase pathways and expression of apoptosis-related proteins. The current study also detected the cell cycle by flow cytometry. Arenobufagin inhibited cell survival and proliferation, decreased the phosphorylation of key downstream proteins of K-Ras, including protein kinase B and extracellular signal related kinase, induced cell cycle G2/M phase arrest and apoptosis, and downregulated the level of phosphorylated epidermal growth factor receptor. Notably, the present data also showed that arenobufagin can enhance the sensitivity of PC cells to gemcitabine and 5-FU. In conclusion, arenobufagin could enhance the effect of gemcitabine and 5-FU on PC cells by targeting multiple key proteins. Therefore, arenobufagin has potential as anadjuvant therapy for the treatment of PC.

20 July 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
LMLin Mu
Lin Mu
ZDZhiguo Dong
Zhiguo Dong
YZYinjian Zhang
Yinjian Zhang
Objective. In this study, we investigated the mechanism of Qing-Gan Li-Shui formulation (QGLSF) in treating primary open glaucoma (POAG) by network pharmacology and in vitro experiments. Methods. The active pharmaceutical ingredients (APIs) of GLQSF (prepared with Prunella vulgaris, Kudzu root, Plantago asiatica, and Lycium barbarum) were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and Yet Another Traditional Chinese Medicine database (YATCM). The targets of POAG were screened out with GeneCards, OMIM, PharmGKB, Therapeutic Target Database (TTD), and DrugBank databases. The Venny platform was used to summarize the core targets. Topological analysis was performed using Cytoscape3.8.0. A protein-protein interaction network was plotted by STRING online. The key targets were subjected to GO and KEGG enrichment analyses. Finally, the effects of APIs were verified by a model of chloride hexahydrate (CoCl2)-induced retinal ganglion cells-5 (RGC-5). Results. The main APIs were selected as quercetin (Que) by network pharmacology. Nine clusters of QGLSF targets were obtained by the PPI network analysis, including AKT-1, TP53, and JUN. KEGG enrichment analysis showed that these targets were mainly involved in the AGE-RAGE signaling pathway. By in vitro experiments, Que promoted cell proliferation. The secretion of AKT-1, TP53, JUN, AGE, and RAGE in the cell culture supernatant decreased, as shown by ELISA. The mRNA levels of AKT-1, TP53, JUN, and RAGE decreased, as shown by RT-PCR. QGLSF may employ the AGE-RAGE signaling pathway to counter POAG. Conclusion. This study preliminarily elucidates the efficacy and mechanism of QGLSF in the treatment of POAG.

22 April 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LMLin Mu
Lin Mu
ZWZhe Wang
Zhe Wang
YCYaojiani Cao
Yaojiani Cao
XWXuejun Wang
Xuejun Wang
XZXingtao Zhou
Xingtao Zhou
Diabetic retinopathy (DR) is a common microvascular complication of diabetes and one of the primary causes of vision loss; however, its pathogenic mechanisms remain largely unresolved. In recent years, immune dysregulation has been increasingly recognized to be closely associated with DR progression. In the present study, we integrated two GEO datasets to identify immune-related differentially expressed genes (DEGs) associated with DR. After batch effect correction and differential expression analysis, a total of 123 immune-related DEGs were identified. Functional enrichment analysis demonstrated that these genes are primarily associated with immune activation pathways, such as T-cell receptor signaling, natural killer cell–mediated cytotoxicity, and IL-17 signaling. Using least absolute shrinkage and selection operator (LASSO) regression, five key genes (IL10RA, PLAUR, PLAU, VTN, and VGF) were identified and used to construct a diagnostic model with excellent predictive performance. Protein–protein interaction and immune infiltration analyses revealed that these genes are closely associated with immune cell activity, particularly the increased infiltration of resting CD4 memory T cells and M2 macrophages in the DR retina. To validate these findings, an STZ-induced diabetic mouse model was used, with key genes further validated at the protein level via Western blot. In addition, consensus clustering was used to stratify patients with DR into two molecular subtypes with distinct immune characteristics and pathway enrichment patterns. Overall, our study elucidates the immune-related mechanisms underlying DR and highlights PLAUR, PLAU, and VGF as potential immune-associated biomarkers, providing a theoretical basis for precision diagnosis and development of targeted immunotherapeutic strategies for DR.